Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 29.7%

Key Points

• Short interest fell 29.7% to 1,904,947 shares as of March 13 (about 4.2% of shares sold short) and the short-interest ratio is just 2.4 days based on average volume.
• Large institutions materially increased stakes—AQR, Arrowstreet and North Peak among them—leaving about 99.67% of the stock owned by institutional investors.
• Wall Street shows a "Moderate Buy" consensus with a $83.89 average price target while shares trade near $53.96 after an earnings beat and FY2026 EPS guidance of $4.90–5.00.

Haemonetics Corporation (NYSE:HAE - Get Free Report) saw a large drop in short interest in the month of March. As of March 13th, there was short interest totaling 1,904,947 shares, a drop of 29.7% from the February 26th total of 2,709,643 shares. Based on an average trading volume of 787,145 shares, the short-interest ratio is currently 2.4 days. Approximately 4.2% of the shares of the company are sold short.

Institutional Trading of Haemonetics

Several large investors have recently added to or reduced their stakes in HAE. AQR Capital Management LLC lifted its stake in shares of Haemonetics by 48.6% during the fourth quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier's stock worth $253,523,000 after purchasing an additional 1,034,226 shares in the last quarter. River Road Asset Management LLC raised its holdings in shares of Haemonetics by 18.7% during the 2nd quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier's stock valued at $122,586,000 after buying an additional 260,624 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in shares of Haemonetics by 994.7% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier's stock valued at $110,615,000 after buying an additional 1,254,035 shares during the period. North Peak Capital Management LLC lifted its position in Haemonetics by 204.4% during the 4th quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier's stock worth $88,405,000 after acquiring an additional 740,626 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Haemonetics by 2.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier's stock worth $53,587,000 after acquiring an additional 26,763 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Citigroup lowered their price objective on Haemonetics from $75.00 to $70.00 and set a "neutral" rating on the stock in a report on Wednesday, March 11th. Mizuho reduced their price target on shares of Haemonetics from $90.00 to $80.00 and set an "outperform" rating for the company in a research report on Friday, February 6th. BTIG Research reissued a "buy" rating and set a $88.00 price target on shares of Haemonetics in a research note on Friday, February 6th. CJS Securities upgraded Haemonetics to a "strong-buy" rating in a report on Thursday, December 11th. Finally, Barrington Research set a $94.00 target price on shares of Haemonetics in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $83.89.

Haemonetics Trading Down 2.8%

Shares of NYSE HAE traded down $1.57 during trading on Friday, hitting $53.96. 1,596,776 shares of the company traded hands, compared to its average volume of 777,816. The firm has a market capitalization of $2.51 billion, a P/E ratio of 14.86, a P/E/G ratio of 1.13 and a beta of 0.28. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. The company has a 50-day moving average price of $62.27 and a 200-day moving average price of $64.97. Haemonetics has a 1 year low of $47.31 and a 1 year high of $87.32.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The company had revenue of $338.97 million for the quarter, compared to the consensus estimate of $331.90 million. During the same period last year, the business posted $1.19 EPS. The company's quarterly revenue was down 2.7% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, equities analysts predict that Haemonetics will post 4.55 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.